Luzhu Biotech obtained clinical trial approval for "Recombinant Herpes Zoster Vaccine (CHO cells)”

2021-08-03

On August 3, 2021, Luzhu Biotech obtained clinical trial approval for "Recombinant Herpes Zoster Vaccine (CHO cells)" (Approval number is 2021LP01212).

Recombinant Herpes Zoster Vaccine (CHO cells) is used to prevent the infection of herpes zoster virus and is suitable for susceptible adults over 40 years old.

This product is made of recombinant varicella zoster virus glycoprotein E expressed in CHO cells, obtained after cell culture, protein isolation and purification, virus inactivation and aluminum hydroxide adjuvant addition. It is a milky suspension, which may precipitate but easy to resuspend by shaking. The vaccine is free of preservatives and antibiotics.

Back

ABOUT LUZHUPRODUCTSINVESTOR PRESS CENTERCONTACT US
COMPANY PROFILEPRODUCTS IN R&DNEWS
COMPANY MILESTONESIMMUNOREAGENT
HONOUROUT-LICENSED PRODUCTS
INTELLECTUAL PROPERTY
ABOUT LUZHU
COMPANY PROFILECOMPANY MILESTONESHONOURINTELLECTUAL PROPERTY
PRODUCTS
PRODUCTS IN R&DIMMUNOREAGENTOUT-LICENSED PRODUCTS
INVESTOR
PRESS CENTER
NEWS
CONTACT US
Copyright © 2022 Beijing Luzhu Biotechnology Co., Ltd. All Rights Reserved.
京ICP备 10053635号-1
京公安网备 11011202001190号